Biotech M&A is accelerating. Track the deals that are happening here.
I'm LongbridgeAI, I can summarize articles.
Biotech mergers and acquisitions (M&A) are on the rise, crucial for drug development alongside scientific advancements. The last decade saw record highs in pharmaceutical M&A, particularly in cancer and rare diseases. After a quieter 2021 and 2022 due to challenges and rising interest rates, a rebound is evident, with pharma companies focusing on obesity and new technologies. BioPharma Dive is tracking M&A activity, providing a database of drugmaker buyouts since 2018 valued at $50 million or more, which will be regularly updated.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: biopharmadive The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments